Related Experiment Video
Updated: Dec 17, 2025
Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Therapeutic Manipulation of mtDNA Heteroplasmy: A Shifting Perspective
Christopher B Jackson1, Doug M Turnbull2, Michal Minczuk3
1Stem Cells and Metabolism, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.
Abstract:
Mutations of mitochondrial DNA (mtDNA) often underlie mitochondrial disease, one of the most common inherited metabolic disorders. Since the sequencing of the human mitochondrial genome and the discovery of pathogenic mutations in mtDNA more than 30 years ago, a movement towards generating methods for robust manipulation of mtDNA has ensued, although with relatively few advances and some controversy. While developments in the transformation of mammalian mtDNA have stood still for some time, recent demonstrations of programmable nuclease-based technology suggest that clinical manipulation of mtDNA heteroplasmy may be on the horizon for these largely untreatable disorders. Here we review historical and recent developments in mitochondrially targeted nuclease technology and the clinical outlook for treatment of hereditary mitochondrial disease.
Insights
Mitochondrial DNA (mtDNA) mutations cause inherited metabolic disorders. New nuclease technologies offer hope for treating these conditions by enabling manipulation of mtDNA heteroplasmy.
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Background:
- Mitochondrial DNA (mtDNA) mutations are a common cause of inherited metabolic disorders.
- Despite over 30 years of research since the human mitochondrial genome was sequenced, effective methods for mtDNA manipulation remain limited.
- Previous advancements in mammalian mtDNA transformation have stalled, leaving many mitochondrial diseases untreatable.
Purpose of the Study:
- To review historical and recent progress in developing mitochondrially targeted nuclease technologies.
- To discuss the potential clinical applications of these technologies for treating hereditary mitochondrial diseases.
Main Methods:
- Review of scientific literature on mtDNA manipulation techniques.
- Analysis of recent developments in programmable nuclease-based technologies.
- Evaluation of the clinical outlook for mtDNA-based therapies.
Main Results:
- Limited progress has been made in robust mtDNA manipulation over the past decades.
- Programmable nuclease technologies show promise for targeting and altering mtDNA heteroplasmy.
- These advancements suggest potential future treatments for currently untreatable mitochondrial disorders.
Conclusions:
- Mitochondrially targeted nuclease technology represents a significant step towards clinical manipulation of mtDNA.
- This technology holds promise for developing novel therapies for hereditary mitochondrial diseases.
- Further research and development are crucial to realize the full clinical potential of these approaches.
Related Concept Videos
01:36Mismatch Repair
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
02:31Homologous Recombination
01:30Spontaneous and Induced Mutations
02:10Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...